The expert group, led by Prof. Dr. Heinz Ludwig (Wilhelminen Cancer Research Institute, Vienna), assessed available clinical trial data together with real-world experience from European practice. Their consensus highlights that melflufen is a valuable treatment alternative for heavily pretreated patients, including elderly patients and those with high-risk disease, with a well-characterized and manageable safety profile.

“Based on both trial data and our clinical experience, we conclude that melflufen offers meaningful benefit to a broad spectrum of patients with relapsed or refractory myeloma, especially those with few remaining therapeutic options,” says Prof. Dr. Heinz Ludwig, lead author of the article. “Our recommendations aim to assist treating physicians in optimizing patient outcomes with melflufen in everyday clinical practice.”

“These expert recommendations add further weight to Pepaxti’s positioning as an effective therapy in later lines of treatment,” says Stefan Norin, Chief Medical Officer at Oncopeptides. “Importantly, they confirm the drug’s utility across different patient subgroups and align with the evidence base from both the pivotal HORIZON and OCEAN studies as well as real-world use.”

The article, “Optimizing the use of melflufen in relapsed or refractory multiple myeloma: Recommendations for clinical practice”, is available online in Annals of Hematology.

For more information, please visit oncopeptides.com, where you will also find a Q&A for investors.